Business Wire

Promising disease modifying approach to Duchenne muscular dystrophy with Neu-REFIX® Beta 1,3-1,6 glucan* from Japan; the first such clinical report.


Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine medications. Clinical improvements published in IBRO Neuroscience reports, might be the world's first such report, wherein, a safe food supplement, mitigated biomarkers of relevance to muscle dysfunction in DMD without side-effects. Increased plasma dystrophin by 32%, indicating improved blood circulation along with muscle strength improvement, is a breakthrough, unraveling the multipronged potential of Neu-REFIX, which also beneficially reconstituted gut microbiome in DMD, gives hope of improving the quality of life and prolonging the life span of DMD patients, opined Dr. Raghavan, the lead author.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Duchenne Muscular Dystrophy (DMD); Progress of disease & gradual disability with aging, current therapies & Neu-REFIX Beta glucans' multipronged potentials, illustrated. A rare genetic disease with approximately 5000 patients in Japan, 3000 in GCC, fewer than 50000 in USA. Lack of dystrophin in DMD causes muscle dysfunction and makes the patient wheelchair bound in early teens. Lung function deterioration followed by myocardial fibrosis and heart failure causing early death in 20s ~ 30s. Gene therapy targets gene defect correction, exon skipping therapies mask the defect of specific exons. Safety proven Neu-REFIX Beta glucans from Japan, a food additive with multipronged potentials: (i) controlled muscle damage, (ii) enhanced muscle regeneration (iii) improved blood supply marker: plasma dystrophin & (iv) improved 6MWT & NSAA, yielding hope of delaying the disease progress, worth further validation; is not a drug or remedy; Not GRAS or EFSA certified. Approval status varies country wise. (Graphic: Business Wire)

Neu-REFIX is an allergen-free ß-glucan, unique for its source, as an exo-polysaccharide from Aureobasidium Pullulans, produced in GMP certified facility in Japan, possessing purity, functionality, water solubility and dosage standardization like a drug, preservable at room temperature, and orally consumable as such or with food. Immune modulatory effects in pre-clinical studies, in healthy Japanese volunteers and Covid-19 patients, showed its potentials as a disease modifying adjuvant, worth undertaking clinical trial in DMD, to yield beneficial effects by controlling inflammation and fibrosis.

Neu-REFIX reduced fibrosis, inflammation, enhanced muscle regeneration, in MDX mice and in a six-month-long clinical study in young boys, improved NSAA, 6MWT and MRC, and these disease modifying potentials were presented in MDA Conference 2023. Neu-REFIX, can be consumed at any stage of DMD, with standard of care medications. Therefore, it’s worth evaluating as a drug-adjuvant because, as reported, Neu-REFIX as a single agent, has helped accomplish, what the current disease modifying treatments, cell-based therapies, and angiogenesis approaches are together, trying to achieve, said Prof. Naoki Yamamoto, a co-researcher.

GNCorp, which spearheaded this accomplishment, has signed a MoU with MAP Healthcare, a subsidiary of SHBK International Holding Group, UAE and intends collaborating with like-minded organizations to validate Neu-REFIX in larger studies. Clinical research in Limb-Girdle Muscle Dystrophy (LGMD) , multiple sclerosis and psoriasis are underway, to evaluate Neu-REFIX’s efficacy as a universal immune modulator.

*B-1,3-1,6 glucan is a listed food additive in MHLW, Japan ; Not a drug or remedy to any illness. Research findings should not be construed as medical advice. Not GRAS, EFSA certified.

To view this piece of content from, please give your consent at the top of this page.

Contact information

Samuel JK Abraham

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Energy Dome's CO2 Battery™ to Revolutionize U.S. Energy Landscape With First Installation Slated for 202622.9.2023 18:45:00 EEST | Press release

A groundbreaking development in sustainable energy storage is on the horizon for Columbia County, Wisconsin, U.S., spearheaded by Alliant Energy in collaboration with Energy Dome and other key stakeholders. Alliant Energy has just announced its selection to receive a federal grant of up to approximately $30 million from the U.S. Department of Energy's Office of Clean Energy Demonstrations (OCED) for the pioneering Columbia Energy Storage Project, a proposed 200-megawatt hour energy storage system, based on Energy Dome’s signature technology: the CO2 Battery™. This visionary battery system, aptly named the “Columbia Energy Storage Project”, is poised to be a trailblazer in the United States, marking a pivotal stride towards a more sustainable, reliable, and cost-effective energy future. Claudio Spadacini, CEO of Energy Dome, declared: “I’m honored to be part of this remarkable journey alongside Alliant Energy. The Columbia Energy Storage Project marks the genesis of a new era, where the

Settlement Administrator Angeion Group Announces Proposed Settlement In U.S. Dollar LIBOR-Based Instrument Class Action22.9.2023 16:00:00 EEST | Press release

There are lawsuits impacting individuals and institutions that entered into over-the-counter financial derivative and non-derivative instruments directly with 17 banks and that received payments tied to U.S. Dollar LIBOR. A Settlement totaling $101 million has been reached with Coöperatieve Rabobank U.A. (“Rabobank”), Lloyds Banking Group plc, Lloyds Bank plc, HBOS plc, and Bank of Scotland plc (together, “Lloyds”), Royal Bank of Canada (“RBC”), and Portigon AG and Westdeutsche Immobilien Servicing AG (together “Portigon”). Earlier settlements totaling $680 million were reached with Barclays, Citibank, Deutsche Bank, HSBC, MUFG, Norinchukin, and SocGen bringing the total settlement amount to $781 million. The remaining Non-Settling Defendants include Bank of America, Credit Suisse, JPMorgan Chase, Royal Bank of Scotland, and UBS. What does the Settlement provide? The Settlement will create a Settlement Fund totaling $101 million that will be used to pay eligible Class Members who submi

Kenvue to Announce Third Quarter 2023 Results on October 26, 202322.9.2023 13:30:00 EEST | Press release

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the third quarter ending October 1, 2023, before market open on October 26, 2023. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its third quarter results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or 201-689-8779 from international locations. A live webcast of the conference call will be available at A replay will be available approximately two hours after the live event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary

OS Achieves 800-Puff Milestone with FEELM Max Technology22.9.2023 12:34:00 EEST | Press release

A significant mark in the vaping industry was set when OS Vape, a pioneering disposable product series from OS, showcased its dynamic range at the InterTabac from September 14th to 16th in Germany. Recognized as a leading brand in Germany's shisha product market, OS boasts an extensive local network of channels. Drawing upon this rich resource base, OS's foray into the disposable e-cigarette domain promises consumers enhanced puff counts, cost-efficiency, and unparalleled vapor consistency. As revealed by Future Marketing Insights, Europe's disposable market witnessed a substantial surge, accounting for a 32.3% revenue share in 2022. This robust growth underscores the escalating consumer preference for hassle-free, smokeless alternatives that eliminate the need for recharges or refills. The evolution of the disposable sector brings heightened convenience and a broader array of choices for consumers. Capitalizing on this trend, OS, through its innovative product series and leveraging it

Earnix Announces New London Office, Unveils New Tech and Launches Global Modelling Contest at Earnix Eˣcelerate Summit 202322.9.2023 11:00:00 EEST | Press release

Earnix, the global provider of intelligent, SaaS solutions for insurers and banks, celebrated its 12th annual Eˣcelerate Summit by announcing a new London office to collaborate with its growing customer base, unveiling Model Accelerator, and launching its first global modelling contest. Held September 20-21 in London, Earnix Eˣcelerate brought together hundreds of financial services business leaders to discuss insurance insights, perspectives, case studies and approaches impacting the evolution of the industry. “Earnix Eˣcelerate was a world-class event dedicated to discussing industry challenges and discovering the latest technology innovation to address them,” said Karun Arathil, senior analyst, Celent. “I found the forum engaging and interactive, and it was great to exchange ideas and gain perspective with industry leaders from around the world.” In other news, Earnix announced a new upgraded office presence in London, located in Devonshire Square. The space affords local employees

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom